Proteasome inhibition and ROS generation by 4-nerolidylcatechol induces melanoma cell death

Pigment Cell and Melanoma Research

Volumn 25, Issue 3, 2012, Pages 354-369

  Brohem, Carla A ^a   Massaro, Renato R ^a   Tiago, Manoela ^a   Marinho, Camila E ^a   Jasiulionis, Miriam G ^b   de Almeida, Rebeca L ^a   Rivelli, Diogo P ^a   Albuquerque, Renata C ^a   de Oliveira, Tiago F ^a   de Melo Loureiro, Ana P ^a   Okada, Sabrina ^a   Soengas, María S ^c   de Moraes Barros, Silvia B ^a   Maria Engler, Silvya S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Structural Biology and Biocomputing Programme   (Spain)

Author keywords

4 nerolidylcatechol; Apoptosis; Artificial skin; Melanoma; Noxa; Proteasomal inhibitor

Indexed keywords

4 NEROLIDYLCATECHOL; ANTINEOPLASTIC AGENT; CATECHOL DERIVATIVE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 4-NEROLIDYLCATECHOL; ANTIOXIDANT; DNA; PROTEASOME; PROTEINASE INHIBITOR; SCAVENGER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MELANOMA; APOPTOSIS; BIOLOGICAL MODEL; DNA FRAGMENTATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; PATHOLOGY; SKIN TUMOR; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CATECHOLS; CELL DEATH; DNA FRAGMENTATION; DNA, NEOPLASM; DRUG EVALUATION, PRECLINICAL; FREE RADICAL SCAVENGERS; HUMANS; MELANOMA; MODELS, BIOLOGICAL; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; REACTIVE OXYGEN SPECIES; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84865310953     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2012.00992.x     Document Type: Article

References (77)

1. Amiri, K.I., Horton, L.W., LaFleur, B.J., Sosman, J.A., and Richmond, A. (2004). Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res. 64, 4912-4918.
2. Averill-Bates, D.A., Ke, Q., Tanel, A., Roy, J., Fortier, G., and Agostinelli, E. (2008). Mechanism of cell death induced by spermine and amine oxidase in mouse melanoma cells. Int. J. Oncol. 32, 79-88.
3. Barros, S.B.M., Teixeira, D.S., Aznar, A.E., Moreira Jr, J.A., Ishii, I., and Freitas, P.C.D. (1996). Antioxidant activity of ethanolic extracts of Pothomorphe umbellata L. Miq. Ciência Culturu. 48, 114-116.
4. Bianchini, F., Jaeckel, A., Vineis, P., Martinez-Garcia, C., Elmstahl, S., Van Kappel, A.L., Boeing, H., Ohshima, H., Riboli, E., and Kaaks, R. (2001). Inverse correlation between alcohol consumption and lymphocyte levels of 8-hydroxydeoxyguanosine in humans. Carcinogenesis 22, 885-890.
5. Boccardo, E., Noya, F., Broker, T.R., Chow, L.T., and Villa, L.L. (2004). HPV-18 confers resistance to TNF-alpha in organotypic cultures of human keratinocytes. Virology 328, 233-243.
6. Brohem, C.A., Sawada, T.C., Massaro, R.R. et al. (2009). Apoptosis induction by 4-nerolidylcatechol in melanoma cell lines. Toxicol. In Vitro 23, 111-119.
7. Brohem, C.A., Cardeal, L.B., Tiago, M., Soengas, M.S., Barros, S.B., and Maria-Engler, S.S. (2010). Artificial skin in perspective: concepts and applications. Pigment Cell Melanoma Res. 24, 35-50.
8. Cadet, J., Douki, T., and Ravanat, J.L. (2008). Oxidatively generated damage to the guanine moiety of DNA: mechanistic aspects and formation in cells. Acc. Chem. Res. 41, 1075-1083.
9. Celeste, A., Fernandez-Capetillo, O., Kruhlak, M.J., Pilch, D.R., Staudt, D.W., Lee, A., Bonner, R.F., Bonner, W.M., and Nussenzweig, A. (2003). Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat. Cell Biol. 5, 675-679.
10. Chandan, R. (2002). Trade in health services. Bull. World Health Org. 80, 158-163.
11. Chao, M.R., Yen, C.C., and HU, C.W. (2008). Prevention of artifactual oxidation in determination of cellular 8-oxo-7,8-dihydro-2'-deoxyguanosine by isotope-dilution LC-MS /MS with automated solid-phase extraction. Free Radical Biol. Med. 44, 464-473.
12. Chen, G., Wang, Y., Garate, M., Zhou, J., and Li, G. (2009). The tumor suppressor ING3 is degraded by SCF(Skp2)-mediated ubiquitin-proteasome system. Oncogene 29, 1498-1508.
13. Chioni, A.M., and Grose, R. (2008). Organotypic modelling as a means of investigating epithelial-stromal interactions during tumourigenesis. Fibrogenesis Tissue Repair 1, 8.
14. Chuang, C.Y., Liu, H.C., Wu, L.C., Chen, C.Y., Chang, J.T., and Hsu, S.L. (2010). Gallic acid induces apoptosis of lung fibroblasts via a reactive oxygen species-dependent ataxia telangiectasia mutatedp53 activation pathway. J. Agric. Food Chem. 58, 2943-2951.
15. Crusio, K.M., King, B., Reavie, L.B., and Aifantis, I. (2010). The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation. Oncogene 29, 4865-4873.
16. Demidem, A., Morvan, D., Papon, J., De Latour, M., and Madelmont, J.C. (2010). Cystemustine induces redifferentiation of primary tumors and confers protection against secondary tumor growth in a melanoma murine model. Cancer Res. 61, 2294-2300.
17. Desmarchelier, C., Slowing, K., and Ciccia, G. (2000). Anti-inflammatory activity of Pothomorphe peltata leaf methanol extract. Fitoterapia 71, 556-558.
18. Dong, L.F., Swettenham, E., Eliasson, J. et al. (2007). Vitamin E analogues inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: the role of oxidative stress. Cancer Res. 67, 11906-11913.
19. ESCODD (European Standards Committee on Oxidative DNA Damage). (2002). Comparative analysis of baseline 8-oxo-7,8-dihydroguanine in mammalian cell DNA, by different methods in different laboratories: an approach to consensus. Carcinogenesis 23, 1129-1133.
20. ESCODD (European Standards Committee on Oxidative DNA Damage), Gedik, C.M., and Collins, A. (2004). Establishing the background level of base oxidation in human lymphocyte DNA: results of an interlaboratory validation study. FASEB J. 18, 82-105.
21. Fernández, Y., Verhaegen, M., Miller, T.P., Rush, J.L., Steiner, P., Opipari Jr, A.W., Lowe, S.W., and Soengas, M.S. (2005). Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res. 65, 6294-6304.
22. Fernández, Y., Miller, T.P., Denoyelle, C., Esteban, J.A., Tang, W.H., Bengston, A.L., and Soengas, M.S. (2006). Chemical blockage of the proteasome inhibitory function of bortezomibe: impact on tumor cell death. J. Biol. Chem. 281, 1107-1118.
23. Flaherty, K.T., Puzanov, I., Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
24. Gaddameedhi, S., and Sancar, A. (2011). Melanoma and DNA damage from a distance (farstander effect). Pigment Cell Melanoma Res. 24, 3-4.
25. Girnita, L., Girnita, A., Brodin, B. et al. (2000). Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res. 60, 5278-5283.
26. Gray-Schopfer, V., Wellbrock, C., and Marais, R. (2007). Melanoma biology and new targeted therapy. Nature 445, 851-857.
27. Greinert, R. (2009). Skin cancer: new markers for better prevention. Pathobiology 76, 64-81.
28. Gustafson, K.R., Cardellina, J.H., McMahon, J.B., Pannell, L.K., Cragg, G.M., and Boyd, M.R. (1992). HIV inhibitory natural products. The peltatols, novel HIV-inhibitory catechol derivatives from Pothomorphe peltata. J. Org. Chem. 57, 2809-2811.
29. Haapajarvi, T., Pitkanen, K., and Laiho, M. (1999). Human melanoma cell line UV responses show independency of p53 function. Cell Growth Differ. 10, 163-171.
30. Hersey, P., and Zhang, X.D. (2001). How melanoma cells evade trail-induced apoptosis. Nat. Rev. Cancer 1, 142-150.
31. Hodi, F.S., O'Day, S.J., McDermott, D.F. et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
32. Ibrahim, N., and Haluska, F.G. (2009). Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu. Rev. Pathol. 4, 551-579.
33. James, S.J., Pogribny, I.P., Pogribna, M., Miller, B.J., Jernigan, S., and Melnyk, S. (2003). Mechanisms of DNA damage, DNA hypomethylation, and tumor progression in the folate/methyl-deficient rat model of hepatocarcinogenesis. J. Nutr. 133, 3740S- 3747S.
34. Jesenberger, V., and Jentsch, S. (2002). Deadly encounter: ubiquitin meets apoptosis. Nat. Rev. Mol. Cell Biol. 3, 112-121.
35. Kijjoa, A., Giesbrecht, A.M., Akisue, M.K., Gottlieb, O.R., and Gottlieb, H.E. (1980). 4-Nerolidylcathecol from Pothomorphe umbellata. Planta Med. 39, 85-87.
36. Koch, O.R., Pani, G., Borrello, S., Colavitti, R., Cravero, A., Farrè, S., and Galeotti, T. (2004). Oxidative stress and antioxidant defenses in ethanol-induced cell injury. Mol. Aspects Med. 25, 191-198.
37. Lecis, D., Drago, C., Manzoni, L. et al. (2010). Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and bortezomib. Br. J. Cancer 102, 1707-1716.
38. Li, H.L., Chen, D.D., Li, X.H., Zhang, H.W., Lu, Y.Q., Ye, C.L., and Ren, X.D. (2002). Changes of NF-kB, p53, Bcl-2 and caspase in apoptosis induced by JTE-522 in human gastric adenocarcinoma cell line AGS cells: role of reactive oxygen species. World J. Gastroenterol. 8, 431-435.
39. Li, G.X., Chen, Y.K., Hou, Z. et al. (2010). Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro. Carcinogenesis 31, 902-910.
40. Mangal, D., Vudathala, D., Park, J.H., Lee, S.H., Penning, T.M., and Blair, I.A. (2009). Analysis of 7,8-dihydro-8-oxo-2'-deoxyguanosine in cellular DNA during oxidative stress. Chem. Res. Toxicol. 22, 788-797.
41. Markovic, S.N., Geyer, S.M., Dawkins, F. et al. (2005). A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103, 2584-2589.
42. Merle, P., Morvan, D., Caillaud, D., and Demidem, A. (2008). Chemotherapy-induced bystander effect in response to several chloroethylnitrosoureas: an origin independent of DNA damage? Anticancer Res. 28, 21-27.
43. Meyskens Jr, F.L., McNulty, S.E., Buckmeier, J.A., Tohidian, N.B., Spillane, T.J., Kahlon, R.S., and Gonzalez, R.I. (2001). Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes. Free Radic Biol Med. 31, 799-808.
44. Miller, L.A., Goldstein, N.B., Johannes, W.U., Walton, C.H., Fujita, M., Norris, D.A., and Shellman, Y.G. (2009). H3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J Invest Dermatol. 129, 964-971.
45. Mousavi-Shafaei, P., Ziaee, A.A., and Zangemeister-Wittke, U. (2009). Increased cytotoxicity of cisplatin in SK-MEL 28 melanoma cells upon down-regulation of melanoma inhibitor of apoptosis protein. Iran. Biomed. J. 13, 27-34.
46. Nakazato, T., Ito, K., Ikeda, Y., and Kizaki, M. (2005). Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. Clin. Cancer Res. 11, 6040-6049.
47. Nihal, M., Ahmad, N., Mukhtar, H., and Wood, G.S. (2005). Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int. J. Cancer 114, 513-521.
48. Nikiforov, M.A., Riblett, M., Tang, W.H. et al. (2007). Tumor cellselective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc. Natl Acad. Sci. U S A 104, 19488-19493.
49. Nishikawa, M., Hyoudou, K., Kobayashi, Y., Umeyama, Y., Takakura, Y., and Hashida, M. (2005). Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. J. Control Rel. 109, 101-107.
50. Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., and Tanaka, N. (2000). Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288, 1053-1058.
51. Pani, G., Koch, O.R., and Galeotti, T. (2009a). The p53-p66shc-manganese superoxide dismutase (MnSOD) network: a mitochondrial intrigue to generate reactive oxygen species. Int. J. Biochem. Cell Biol. 41, 1002-1005.
52. Pani, G., Giannoni, E., Galeotti, T., and Chiarugi, P. (2009b). Redoxbased escape mechanism from death: the cancer lesson. Antioxid. Redox Signal. 11, 2791-2806.
53. Paraiso, K.H., Fedorenko, I.V., Cantini, L.P., Munko, A.C., Hall, M., Sondak, V.K., Messina, J.L., Flaherty, K.T., and Smalley, K.S. (2010). Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 102, 1724-1730.
54. Pérez-Galán, P., Roué, G., Villamor, N., Montserrat, E., Campo, E., and Colomer, D. (2006). The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107, 257-264.
55. Ploner, C., Kofler, R., and Villunger, A. (2008). Noxa: at the tip of the balance between life and death. Oncogene 27, S84-S92.
56. Podhorecka, M., Skladanowski, A., and Bozko, P. (2010). H2AX phosphorylation: its role in DNA damage response and cancer therapy. J. Nucl. Acids Pii, 920161.
57. Ravanat, J.L., Douki, T., Duez, P., Gremaud, E., Herbert, K., Hofer, T., Lasserre, L., Saint-Pierre, C., Favier, A., and Cadet, J. (2002). Cellular background level of 8-oxo-7,8-dihydro-2'-deoxyguanosine: an isotope based method to evaluate artefactual oxidation of DNA during its extraction and subsequent work-up. Carcinogenesis 23, 1911-1918.
58. Ribeiro, D.A., Salvadori, D.M., and Marquez, M.E. (2005). Abnormal expression of bcl-2 and bax in rat tongue mucosa during the development of squamous cell carcinoma induced by 4-nitroquinoline 1-oxide. Int. J. Exp. Pathol. 86, 375-381.
59. Rieber, M., and Rieber, M.S. (1999). Tumor suppression without differentiation or apoptosis by antisense cyclin D1 gene transfer in K1735 melanoma involves induction of p53, p21WAF1 and superoxide dismutases. Cell Death Differ. 6, 1209-1215.
60. Roberti, A., Rizzolio, F., Lucchetti, C., de Leval, L., and Giordano, A. (2011). Ubiquitin-mediated protein degradation and methylationinduced gene silencing cooperate in the inactivation of the INK4/ARF locus in Burkitt lymphoma cell lines. Cell Cycle 10, 127-134.
61. Roberts, R.J. (1995). On base flipping. Cell 82, 9-12.
62. Ropke, C.D., Kaneko, T.M., Rodrigues, R.M., da Silva, V.V., Barros, S., Sawada, T.C., Kato, M.J., and Barros, S.B. (2002). Evaluation of percutaneous absorption of 4-nerolidylcathecol from four topical formulations. Int. J. Pharm. 249, 109-116.
63. Ropke, C.D., da Silva, V.V., Kera, C.Z., Miranda, D.V., de Almeida, R.L., Sawada, T.C., and Barros, S.B. (2006). In vitro and in vivo inhibition of skin matrix metalloproteinases by Pothomorphe umbellata root extract. Photochem. Photobiol. 82, 439-442.
64. Seeger, J.M., Schmidt, P., Brinkmann, K. et al. (2010). The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack. Cancer Res. 70, 1825-1834.
65. Sies, H. (1993). Strategies of antioxidant defense. Eur. J. Biochem. 215, 213-219.
66. Silva, R.A.D. (1926). Pharmacopéia dos Estados Unidos do Brasil. (São Paulo: Nacional), 649.
67. Smalley, K.S., and Sondak, V.K. (2010). Melanoma - an unlikely poster child for personalized cancer therapy. N. Engl. J. Med. 363, 876-878.
68. Soengas, M.S., and Lowe, S.W. (2003). Apoptosis and melanoma chemoresistance. Oncogene 22, 3138-3151.
69. Sorolla, A., Yeramian, A., Dolcet, X. et al. (2008). Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines. Br. J. Dermatol. 158, 496-504.
70. Su, Y., Amiri, K.I., Horton, L.W., Yu, Y., Ayers, G.D., Koehler, E., Kelley, M.C., Puzanov, I., Richmond, A., and Sosman, J.A. (2010). A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin. Cancer Res. 16, 348-357.
71. Tawbi, H., and Nimmagadda, N. (2009). Targeted therapy in melanoma. Biologics 3, 475-484.
72. Thomas, N.E., Edmiston, S.N., Alexander, A. et al. (2007). Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev. 16, 991-997.
73. Tormo, D., Checińska, A., Alonso-Curbelo, D. et al. (2009). Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell 16, 103-114.
74. Verhaegen, M., Bauer, J.A., Martín de la Vega, C. et al. (2006). A novel BH3 mimetic reveals a mitogen-activated protein kinasedependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res. 66, 11348-11359.
75. Wolter, K.G., Verhaegen, M., Fernández, Y., Nikolovska-Coleska, Z., Riblett, M., de la Vega, C.M., Wang, S., and Soengas, M.S. (2007). Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ. 14, 1605-1616.
76. Yauk, C., Polyzos, A., Rowan-Carroll, A. et al. (2008). Germ-line mutations, DNA damage, and global hypermethylation in mice exposed to particulate air pollution in an urban/industrial location. PNAS 105, 605-610.
77. Yoshino, M., Haneda, M., Naruse, M., Htay, H.H., Iwata, S., Tsubouchi, R., and Murakami, K. (2002). Prooxidant action of gallic acid compounds: copper-dependent strand breaks and the formation of 8-hydroxy-2 O-deoxyguanosine in DNA. Toxicol. In Vitro 16, 705-709.